Description: Regencell Bioscience Holdings Limited operates a traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Home Page: www.regencellbioscience.com
RGC Technical Analysis
First Commercial Building
Causeway Bay,
Hong Kong
Phone:
852 2155 0823
Officers
| Name | Title |
|---|---|
| Mr. Yat-Gai Au | Founder, Chairman & CEO |
| Ms. Michelle Chan | Financial Controller |
| Mr. Wai Hong Chung | COO & Chief Strategy Officer |
| Dr. Yi-Chung Chao Ph.D. | Chief Medical Officer & Director |
| Mr. Tien Hsiang Chau | Exec. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 23.3405 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-07-16 |
| Fiscal Year End: | June |
| Full Time Employees: | 13 |